Biomarkers for the antiangiogenic effects of ATN-224
Author Information
Author(s): Doñate F, Juarez J C, Burnett M E, Manuia M M, Guan X, Shaw D E, Smith E L P, Timucin C, Braunstein M J, Batuman O A, Mazar A P
Primary Institution: Attenuon, LLC
Hypothesis
Can biomarkers be identified to track the activity of the SOD1 inhibitor tetrathiomolybdate (ATN-224) in cancer treatment?
Conclusion
Both SOD activity measurements and levels of endothelial progenitor cells may serve as useful biomarkers for the antiangiogenic activity of ATN-224.
Supporting Evidence
- ATN-224 treatment inhibited SOD activity in blood cells in a dose-dependent manner.
- Endothelial progenitor cells decreased significantly after ATN-224 treatment.
- SOD activity in blood cells was rapidly inhibited at doses that maximally inhibited angiogenesis.
Takeaway
This study looks for signs in the blood that show how well a new cancer drug works at stopping blood vessel growth.
Methodology
The study involved preclinical evaluations in mice and bonnet macaques, measuring SOD activity and endothelial progenitor cells after ATN-224 treatment.
Limitations
The study primarily used animal models, which may not fully predict human responses.
Participant Demographics
Three female and three male bonnet macaques, mean age 12.9 years.
Statistical Information
P-Value
p=0.012
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website